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Background: Gefitinib and erlotinib are two orally active epidermal
growth factor receptor tyrosine kinase inhibitors used in the treat-
ment of advanced non-small cell lung cancer (NSCLC). Gefitinib
was the first one to become available in Europe in an expanded
access program. When erlotinib granted approval, there were
many patients who had progressed after receiving gefitinib and
different lines of chemotherapy with no further treatment options;
moreover, the results of clinical trials suggested possible signif-
icant differences in the mechanisms of sensitivity and in the
efficacy between these two agents.
Methods: Advanced NSCLC White patients, previously treated
with almost two lines of chemotherapy and with gefitinib, obtaining
a partial response or a stable disease with this agent, were treated
with erlotinib after progression of disease to gefitinib. Only eight
patients resulted eligible because of the unavailability of gefitinib
after the closure of the expanded access program.
Results: Four patients were women; histologic diagnosis was ade-
nocarcinoma in four cases and bronchoalveolar carcinoma or un-
specified NSCLC in two cases each. Median age was 70 years
(range, 53–85). Seven out of eight patients had never smoked, one
was a former smoker.
We obtained two partial responses and three stable diseases
with erlotinib with a median duration of response of 8 months. The
median time to progression and overall survival were 5.9 and 14.6
months, respectively.
Conclusion: Erlotinib seems to be a potential therapeutic option for
treatment of selected advanced NSCLC patients after failure of
gefitinib. Further studies are warranted to evaluate the molecular
mechanisms behind this evidence and clarify how to select patients
for treatment with epidermal growth factor receptor tyrosine kinase
inhibitors.
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The epidermal growth factor receptor (EGFR) is a potentialtarget for the therapy for non-small cell lung cancer
(NSCLC) for its role in the control of cell survival, prolifer-
ation, metastasis, and angiogenesis. Strategies for its block-
ade include inhibition of the intracellular tyrosine kinase
domain by small molecules such as gefitinib or erlotinib.1
Gefitinib was the first EGFR tyrosine kinase inhibitor
(TKI) to become available in Europe in an expanded access
program in pretreated advanced NSCLC on the basis of the
results of two large randomized phase II studies.2,3 Neverthe-
less, the Iressa Survival Evaluation in Lung Cancer phase III
trial comparing gefitinib with best supportive care among
1692 advanced NSCLC patients pretreated with one or two
prior chemotherapy regimens, did not show a significant
difference in overall survival between gefitinib and placebo
(5.6 versus 5.1 month; hazard ratio, 0.89; 95% confidence
interval, 0.78–1.03; p  0.11).4 On the contrary, erlotinib
showed a survival benefit versus placebo in patients with
NSCLC after the failure of first-line or second-line chemo-
therapy in the BR.21 randomized phase III trial (6.7 versus
4.7 months; p  0.001).5
When erlotinib granted approval, there were several pa-
tients, pretreated and progressed after gefitinib, who had no
further treatment options, but were still in good general condi-
tions; moreover, the results of clinical trials suggested that
erlotinib could be more efficacious than gefitinib, and there was
no evidences of cross-resistance between the two drugs.5,6
For these reasons, we carried out a study to evaluate the
activity of erlotinib in advanced NSCLC patients pretreated
with at least two lines of chemotherapy who had previously
obtained a disease control with gefitinib.
PATIENTS AND METHODS
White patients with histologic or cytologic diagnosis of
NSCLC in advanced stage (IIIB for pleural effusion or
supraclavicular lymph nodes or IV) pretreated with at least
two lines of chemotherapy entered in the study, if they had
obtained a partial response (PR) or a stable disease (SD)
longer than 6 months with gefitinib 250 mg per day orally.
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After progressive disease (PD) to gefitinib, patients re-
ceived erlotinib 150 mg once daily PO until PD, unacceptable
toxicity or refusal. One dose reduction per patient from 150 mg
to 100 mgwas permitted; the administration of the drug could be
interrupted for a maximum of 21 days in case of toxicity.
The accrual of the study was stopped early because of the
unavailability of gefitinib after the closure of the expanded
access program on the basis of the results of ISEL study.
Baseline evaluations included a complete medical his-
tory, physical examination, complete blood chemistry, and
hematology. Evaluation of treatment response was repeated
every 8 weeks by computed tomography according to re-
sponse evaluation criteria in solid tumors criteria.7 Disease
control was defined as the sum of complete and PR and SD
substained for 60 days or longer.8
Time to progression (TTP) was defined as the period
from the start of treatment to the date of PD or death,
whichever occurred first; overall survival was defined as the
period from the start of treatment to the date of death.
Comparison among response and clinical informa-
tion were performed using Pearson 2 tests (for categorical
variables).
Adverse events were recorded every 4 weeks according
to the National Cancer Institute Common Terminology Cri-
teria version 3.0.
RESULTS
From October 2006 to May 2007, eight patients were
enrolled into the study; four (50%) patients were women and
four men; histologic diagnosis was adenocarcinoma in four
cases (50%), and bronchoalveolar carcinoma and unspecified
NSCLC in other two cases each (25%); the median number of
previous treatment regimens was three. Median age was 70
years (range, 53–85). One patient had a performance status
(PS)  0 (12.5%), four patients had a PS  1 (50%), and three
patients had a PS  2 (37.5%). Seven out of eight patients
(87.5%) had never smoked whereas the other one was a former
smoker who quit smoking from 6 years (12.5%).
Four patients had previously obtained a PR and the
other four patients a SD longer than 6 months with gefitinib;
the median TTP with gefitinib was 17 months.
After treatment with erlotinib, we observed 2 (25%) PR
and 3 (37.5%) SD, with a median duration of disease control
of 8 months, whereas 3 patients experienced a PD. The
median TTP and overall survival with erlotinib were 5.9 and
14.6 months, respectively.
At an exploratory analysis, we observed that those
patients who have obtained disease control with erlotinib, had
showed a longer TTP to previous gefitinib than those who
have progressed during erlotinib treatment. In fact, the five
patients who have achieved PR or SD with erlotinib had
obtained a median TTP of 18 months with gefitinib, whereas
the three patients who have progressed with erlotinib had
presented a shorter median TTP with gefitinib of 8.5 months.
Toxicities were acceptable with grade 3 skin toxicity
only in one patient requiring a brief drug interruption and
dose reduction of erlotinib at 100 mg per day; grade 1 and
grade 2 skin toxicities were reported in three and one patients,
respectively, whereas grade 1 diarrhea occurred in three patients.
DISCUSSION
In this small study, erlotinib seemed to be able to confer
a benefit in patients with advanced NSCLC selected for
clinical positive predictive factors progressed after having
received gefitinib. In particular, in our series, we obtained a
disease control rate of 62.5% with a median duration of this
control of 8 months. These data might reflect the particular
natural history of the disease, but the response rate of 25%
that we obtained was of interest.
Some small studies of treatment with a different EGFR
TKI after failure of a previous inhibitor (erlotinib after gefitinib
or vice versa) have been published in the last years8–15 and some
others have been reported only as abstracts.16–18 The only one
published prospective phase II study is that reported by Cho et
al.,8 in a recent issue of Journal of Clinical Oncology, discussing
the efficacy and toxicity of erlotinib in 21 patients with advanced
NSCLC progressed after treatment with gefitinib. The authors
obtained a response rate and a disease control rate of 9.5% and
28.6%, respectively, with a median TTP and OS of 60 days and
158 days. The patients enrolled in this last study were not
selected for the previous response to gefitinib, so that 11 refrac-
tory patients were also included.
Gridelli et al.9 recently reported three cases of patients
selected for a previous response to gefitinib, obtaining one PR
and two long-lasting SDs with erlotinib. On the contrary,
Viswanathan et al.11 described five patients who developed
PD with erlotinib used after progression to gefitinib; four out
of these five patients have previously had a disease control
with gefitinib.
At our knowledge, a total of 93 cases, including our series,
of patients treated with erlotinib after failure of gefitinib were
described with 11 responses (11.8%) and 22 SD (23.6%); a
disease control with erlotinib was obtained in 30 patients
(46.1%) out of 65 who have had a disease control also with
gefitinib, whereas only 3 out of 28 patients who have progressed
with gefitinib, responded to erlotinib (p  0.001) (Table 1).
TABLE 1. Experiences with Erlotinib after Failure of Gefitinib
Author
No. of
Patients
Response to
Prior Gefitinib
Response to
Erlotinib
PR SD PD PR SD PD
Vasile (current study) 8 4 4 — 2 3 3
Cho8 21 6 4 11 2 4 15
Gridelli9 3 — 3 — 1 2 —
Viswanathan11 5 — 4a 1 — — 5
Garfield10 1 — — 1 1 — —
Walther12 1 — — 1 1 — —
Chang13 1 1 — — 1 — —
Sim16 14 6 4 4 1 1 12
Wong15 14 — 9a 5 — 5a 9
Shih17 25 — 20a 5 2 7 16
a Reported only the disease control rate (as the sum of PR and SD).
PR, partial response; SD, stable disease; PD, progressive disease.
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Sixteen cases treated with the inverse sequence were
reported with 1 PR (6.3%) and 6 SD (37.5%); among the
seven patients who had obtained a disease control with
erlotinib, 6 (85.7%) patients have reported a disease control
also with gefitinib versus only one patient among nine who
had progressed with erlotinib (p  0.003).
These results are surprising because both EGFR TKIs
share the same activity of EGFR blockade. The molecular
mechanisms behind this double sensitivity are not yet com-
pletely discovered.
Cho et al. reported that erlotinib could be active in
some gefitinib-resistant tumors because erlotinib may be
more efficacious than gefitinib on wild-type EGFR or because
there could be differences in the biologically equivalent dose
of the two drugs in favor of erlotinib; however, these expla-
nations do not justify the observation of a possible activity of
gefitinib after failure of erlotinib in some patients.
Many somatic mutations in EGFR gene have been
described in NSCLC patients and associated with sensitivity
or resistance to EGFR TKI; the relationship among different
mutations and the activity of the two TKIs has not been
completely studied. For example, it was reported that the
combination of two different mutations could confer resis-
tance to a TKI but improve sensitivity to the other one.19
Moreover, it was showed that some tumor cells remain
sensitive to EGFR blockade even after the progression of
treatment with EGFR TKI.20
From a clinical point of view, the study of the correla-
tion between biologic parameters and the clinical outcome of
the two EGFR-TKIs will clarify how to select individual
patients for the treatment with the most effective EGFR TKI
or for sequential treatment with different TKIs, therapy with
a different EGFR TKI could be evaluated after the failure of
a previous TKI in patients who had obtained disease control
with the first TKI; a longer TTP after the first TKI could be
a possible positive predictive factor for the activity of the
second TKI.
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